← Eichor
Study identifier: NCT02269592 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Condition: Monoclonal Gammopathy of Undetermined Significance (MGUS) · Myelodysplastic Syndromes · Hematological Malignancies  ·  Sponsor: Dana-Farber Cancer Institute

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered. Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study. This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have…

This description comes directly from the study's public registry record.

Talk to the study team

Irene Ghobrial, MD  ·  617-632-4198  ·  precursor@partners.org

Always discuss trial participation with your own doctor first.

Locations (7)

Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Dana Farber Cancer Institute at St. Elizabeth'sBrighton, Massachusetts, United StatesRecruiting
Dana Farber Cancer Institute at Merrimack ValleyMethuen, Massachusetts, United StatesRecruiting
Dana Farber Cancer Institute at Milford Regional Medical CenterMilford, Massachusetts, United StatesRecruiting
Dana Farber Cancer Institute at South ShoreWeymouth, Massachusetts, United StatesRecruiting
West Michigan Cancer CenterKalamazoo, Michigan, United StatesRecruiting
Dana Farber/New Hampshire Oncology-HematologyLondonderry, New Hampshire, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02269592